Evidence reviews 2020
In 2020, we reviewed the evidence in the following areas and made recommendations (labelled [2020]):
- Dual antiplatelet therapy
- Early invasive versus conservative management
- Antithrombin therapy
- Antithrombin therapy in adults with ST-segment elevation myocardial infarction intended for primary percutaneous coronary intervention
- Culprit vessel only compared to complete revascularisation
- Clinical and cost effectiveness of drug-eluting stents
- Antiplatelet therapy for people with an ongoing separate indication for anticoagulation
- Beta-blockers
This page was last updated: